These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 20214321)

  • 21. Virus neutralizing antibodies at different stages of the HIV disease: increased levels after azidothymidine treatment.
    Schmidtmayerová H; Lackovicová M; Stanková M; Brůcková M; Surový I; Ujhelyi E; Füst G; Mayer V
    Acta Virol; 1992 Mar; 36(2):157-65. PubMed ID: 1359767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.
    Kelly HR; Urbanski M; Burda S; Zhong P; Konings F; Nanfack J; Tongo M; Kinge T; Achkar J; Nyambi P
    Hum Antibodies; 2005; 14(3-4):89-99. PubMed ID: 16720979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapping the sanguine humor: broadly neutralizing antibodies stole the show at Keystone.
    McEnery R
    IAVI Rep; 2012; 16(2):10-4. PubMed ID: 22650054
    [No Abstract]   [Full Text] [Related]  

  • 24. Durable neutralizing antibodies after remote smallpox vaccination among adults with and without HIV infection.
    Kan VL; Manischewitz J; King LR; Golding H
    AIDS; 2007 Feb; 21(4):521-4. PubMed ID: 17301573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
    Haynes BF; Montefiori DC
    Expert Rev Vaccines; 2006 Aug; 5(4):579-95. PubMed ID: 16989638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dozens of new broadly neutralizing antibodies identified.
    von Bubnoff A
    IAVI Rep; 2011; 15(4):18-9. PubMed ID: 21936311
    [No Abstract]   [Full Text] [Related]  

  • 27. The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.
    Vogel T; Kurth R; Norley S
    J Immunol; 1994 Aug; 153(4):1895-904. PubMed ID: 7519220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Researchers gather clues about how broadly neutralizing antibodies develop.
    von Bubnoff A
    IAVI Rep; 2011; 15(4):19. PubMed ID: 21936312
    [No Abstract]   [Full Text] [Related]  

  • 30. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1.
    Lakhashe SK; Kulkarni SS; Thakar MR; Ghate MV; Paranjape RS
    Virology; 2007 Mar; 359(2):295-301. PubMed ID: 17074379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men.
    Hasselrot K; Säberg P; Hirbod T; Söderlund J; Ehnlund M; Bratt G; Sandström E; Broliden K
    AIDS; 2009 Jan; 23(3):329-33. PubMed ID: 19114861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 33. Neutralizing antibody responses to HIV-1 infection.
    Morris L
    IUBMB Life; 2002; 53(4-5):197-9. PubMed ID: 12120994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals.
    Tamalet C; Simon F; Dhiver C; Matheron S; de Micco P; Gastao JA; Brun-Vézinet F
    AIDS; 1995 Jan; 9(1):90-1. PubMed ID: 7893447
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates.
    Jolly PE; Weiss HL
    Virology; 2000 Jul; 273(1):52-9. PubMed ID: 10891407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying broadly neutralizing antibody activity in HIV-infected individuals.
    Kresge KJ
    IAVI Rep; 2009; 13(3):18. PubMed ID: 20214321
    [No Abstract]   [Full Text] [Related]  

  • 38. Study describes onset of broadly neutralizing antibody responses in HIV-infected individuals.
    von Bubnoff A
    IAVI Rep; 2011; 15(1):23. PubMed ID: 21449508
    [No Abstract]   [Full Text] [Related]  

  • 39. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Researchers make immunogen that can bind to precursors of broadly neutralizing antibodies.
    von Bubnoff A
    IAVI Rep; 2011; 15(5):22-3. PubMed ID: 22121551
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.